Convergent and Divergent Signaling Pathways in Cancer: A Dual‑Axis Model for Adaptive Precision Oncology
Cancer progression is driven by the convergence of diverse oncogenic drivers onto core signaling pathways (e.g., MAPK, PI3K/AKT, Wnt/β‑catenin) and the downstream divergence of adaptive responses, underscoring the need for integrative therapeutic strategies that address both shared vulnerabilities and tumor‑specific resistance mechanisms.
This review explores how oncogenes and signaling pathways converge and diverge in cancer, shaping diagnostic and therapeutic strategies for personalized interventions.
Understanding the convergence of actionable pathways and their downstream divergent adaptations is crucial to developing therapies that are both effective and durable across diverse tumor types.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT